Tag: Bio-Path Holdings

November 21, 2019

Bio-Path’s Shares Dip on IND Application Approval

The FDA has approved Bio-Path's IND for its second drug candidate, but the news sent the company's shares down over...
November 21, 2019

Bio-Path Holdings Receives FDA Clearance for BP1002

A Phase 1 clinical trial will now evaluate BP1002's ability to treat refractory/relapsed lymphoma and chronic lymphocytic leukemia.
August 26, 2019

Bio-Path Doses Patient in Amended Phase 2 Prexigebersen Trial

Bio-Path Holdings (NASDAQ:BPTH) has announced patient dosing in its amended Phase 2 trial of prexigebersen to treat acute myeloid leukemia...